Beromun (tasonermin)
- Region
- 🇪🇺 EU
- Active substance
- tasonermin
- Company
- Belpharma s.a.
- Status
- Authorised
- Therapeutic area
- Sarcoma
- EU approval
- Mon 12 Apr 1999
- Application
- EMEA/H/C/000206
- ATC
- L03AX11
- Official record
- www.ema.europa.eu
Indication
Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP).
Regulatory milestones
No milestones recorded in the last year.
Follow Beromun
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.